nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.03.2020 | Original Article – Clinical Oncology

ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm

verfasst von: Yuanyuan Liu, Shafei Wu, Xiaohua Shi, Zhiyong Liang, Xuan Zeng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

IHC, FISH, and NGS are common methods of ALK evaluation in NSCLC. The purpose of this study was to investigate whether ALK false positives or false negatives occurred more often in daily routines. An approach to identify ALK fusion was then proposed.

Materials and methods

We analyzed 1815 cases of NSCLC, including 83 (4.6%) ALK IHC positives. Total 182 samples (62 ALK+ and 120 ALK−) were examined via FISH, RT-ddPCR, NGS, RT-qPCR and RNAscope to confirm ALK status.

Results

One ALK FISH false negative was found, which harbored two genomic rearrangements involved in EML4–ALK (exon 13:exon 20) fusion. One ALK IHC false negative was confirmed depending on a rare ALK FISH-positive pattern and ALK RNAscope positive but ALK fusion was not found via NGS. In addition, an atypical ALK FISH-positive pattern was observed in an IHC-positive case with chromosome 2 inversion leading to EML4–ALK (exon 6:exon 20) fusion. EML4–ALK fusion was determined in one case with an atypical FISH patterns by RT-qPCR. Rare complicated genomic rearrangements involved in a novel ALK fusion of EML4–ALK (exon 7:exon 14) were distinguished in an ALK IHC and FISH double-positive case.

Conclusion

False negative of ALK IHC, FISH and NGS results were found in our cohort, but none was false ALK positive. False ALK negatives should be more concerned than false positives. ALK rearrangements with cryptic ALK fusion patterns could be identified using our algorithm. Non-squamous non-small cell lung cancer was recommended for priority detection.

Christopoulos P, Endris V, Bozorgmehr F et al (2018) EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. Int J Cancer 142:2589–2598. https://doi.org/10.1002/ijc.31275 CrossRefPubMed

Conklin CM, Craddock KJ, Have C et al (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8:45–51. https://doi.org/10.1097/JTO.0b013e318274a83e CrossRefPubMed

Grimm EE, Schmidt RA, Swanson PE et al (2010) Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 134:284–292. https://doi.org/10.1309/AJCPUQB18XZOHHBJ CrossRefPubMed

Guyard A, Charpy C, Théou-Anton N et al (2019) Isolated 5' signals are an atypical pattern to be considered as positive for ALK rearrangement: a brief report of three cases and review of the literature. Transl Oncol 12:784–787. https://doi.org/10.1016/j.tranon.2019.02.015 CrossRefPubMedPubMedCentral

Heuckmann JM, Pauwels P, Thunnissen E et al (2017) Comprehensive hybrid capture-based next-generation sequencing identifies a double ALK gene fusion in a patient previously identified to be false-negative by FISH. J Thorac Oncol 12:e22–e24. https://doi.org/10.1016/j.jtho.2016.11.2229 CrossRefPubMed

Katayama R, Lovly CM, Shaw AT (2015) Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21:2227–2235. https://doi.org/10.1158/1078-0432.CCR-14-2791 CrossRefPubMedPubMedCentral

Kim HS, Jung M, Kang HN et al (2017) Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene 36:3334–3345. https://doi.org/10.1038/onc.2016.486 CrossRefPubMed

Li T, Maus MK, Desai SJ et al (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18–25. https://doi.org/10.1097/JTO.0000000000000030 CrossRefPubMed

Li W, Zhang J, Guo L et al (2017) Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 12:94–101. https://doi.org/10.1016/j.jtho.2016.08.145 CrossRefPubMed

Lindeman NI, Cagle PT, Aisner DL et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 13:323–358. https://doi.org/10.1016/j.jtho.2017.12.001 CrossRefPubMed

Lv X, Zhao M, Yi Y et al (2017) Detection of rare mutations in ctDNA using next generation sequencing. J Vis Exp. https://doi.org/10.3791/56342 CrossRefPubMedPubMedCentral

McLeer-Florin A, Duruisseaux M, Pinsolle J et al (2018) ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer 116:15–24. https://doi.org/10.1016/j.lungcan.2017.12.004 CrossRefPubMed

Minca EC, Portier BP, Wang Z et al (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15:341–346. https://doi.org/10.1016/j.jmoldx.2013.01.004 CrossRefPubMed

Nakajima N, Yoshizawa A, Kondo K et al (2017) Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement. Histopathology 71:143–149. https://doi.org/10.1111/his.13198 CrossRefPubMed

Niu X, Chuang JC, Berry GJ et al (2017) Anaplastic lymphoma kinase testing: IHC vs. FISH vs. NGS. Curr Treat Options Oncol 18:71. https://doi.org/10.1007/s11864-017-0513-x CrossRefPubMed

Peled N, Palmer G, Hirsch FR et al (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7:e14–16. https://doi.org/10.1097/JTO.0b013e3182614ab5 CrossRefPubMedPubMedCentral

Poirot B, Doucet L, Benhenda S et al (2017) MET Exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels. J Thorac Oncol 12:1582–1587. https://doi.org/10.1016/j.jtho.2017.07.026 CrossRefPubMed

Qiu Y, Li B, Zhang Y et al (2019) ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: a case report. Medicine (Baltimore) 98:e14826. https://doi.org/10.1097/MD.0000000000014826 CrossRef

Ren S, Hirsch FR, Varella-Garcia M et al (2014) Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 9:e21–23. https://doi.org/10.1097/JTO.0000000000000013 CrossRefPubMedPubMedCentral

Sasaki T, Rodig SJ, Chirieac LR et al (2010) The biology and treatment of EML4–ALK non-small cell lung cancer. Eur J Cancer 46:1773–1780. https://doi.org/10.1016/j.ejca.2010.04.002 CrossRefPubMedPubMedCentral

Selinger C, Cooper W, Lum T et al (2015) Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology 67:654–663. https://doi.org/10.1111/his.12708 CrossRefPubMed

Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253. https://doi.org/10.1200/JCO.2009.22.6993 CrossRefPubMedPubMedCentral

Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566CrossRef

Soda M, Takada S, Takeuchi K et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105:19893–19897. https://doi.org/10.1073/pnas.0805381105 CrossRefPubMed

Thai AA, Solomon BJ (2018) Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol 30:84–91. https://doi.org/10.1097/CCO.0000000000000431 CrossRefPubMed

Tian HX, Zhang XC, Yang JJ et al (2017) Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer 114:90–95. https://doi.org/10.1016/j.lungcan.2017.11.001 CrossRefPubMed

Tong Y, Zho Z, Liu B et al (2018) 5'/ 3′ imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer. J Exp Clin Cancer Res 37:68. https://doi.org/10.1186/s13046-018-0735-1 CrossRefPubMedPubMedCentral

Tuononen K, Mäki-Nevala S, Sarhadi VK et al (2013) Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 52:503–511. https://doi.org/10.1002/gcc.22047 CrossRefPubMed

Wang Y, Liu Y, Zhao C et al (2016) Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. Lung Cancer 94:28–34. https://doi.org/10.1016/j.lungcan.2016.01.014 CrossRefPubMed

Wang J, Yi Y, Xiao Y et al (2019) Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 32:1053–1064. https://doi.org/10.1038/s41379-019-0212-1 CrossRefPubMed

Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738 CrossRefPubMed

Wynes MW, Sholl LM, Dietel M et al (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9:631–638. https://doi.org/10.1097/JTO.0000000000000115 CrossRefPubMedPubMedCentral

Zhang XC, Lu S, Zhang L et al (2018) Guideline for diagnosis and treatment of ALK and ROS1 positive non-small cell lung cancer in China. Zhonghua Bing Li Xue Za Zhi 47:241–247. https://doi.org/10.3760/cma.j.issn.0529-5807.2018.04.003 CrossRefPubMed

Zhao W, Choi YL, Song JY et al (2016) ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 94:22–27. https://doi.org/10.1016/j.lungcan.2016.01.011 CrossRefPubMed

Zhu X, Liu B, Su S et al (2020) A "quasi" confocal droplet reader based on laser-induced fluorescence (LIF) cytometry for highly-sensitive and contamination-free detection. Talanta 206:120200. https://doi.org/10.1016/j.talanta.2019.120200 CrossRefPubMed

Zhu X, Su S, Fu M et al (2019) A density-watershed algorithm (DWA) method for robust, accurate and automatic classification of dual-fluorescence and four-cluster droplet digital PCR data. Analyst 144:4757–4771. https://doi.org/10.1039/c9an00637k CrossRefPubMed

Zito Marino F, Rocco G, Morabito A et al (2016) A new look at the ALK gene in cancer: copy number gain and amplification. Expert Rev Anticancer Ther 16:493–502. https://doi.org/10.1586/14737140.2016.1162098 CrossRefPubMed

Zito Marino F, Rossi G, Brunelli M et al (2017) Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: cytological smears versus cell blocks. Cancer Cytopathol 125:303–312. https://doi.org/10.1002/cncy.21835 CrossRefPubMed

Titel: ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
verfasst von: Yuanyuan Liu
Shafei Wu
Xiaohua Shi
Zhiyong Liang
Xuan Zeng
Publikationsdatum: 03.03.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03166-1

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFβ signaling in colorectal cancer

Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy

Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations

Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study

Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

Predictors of the regional variation of prostatectomy or radiotherapy: evidence from German cancer registries

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie